COVID Treatment

Approximately 2 years after patients were infected with COVID-19, non-hospitalized patients suffered from post-COVID-19 symptoms nearly 8% more than hospitalized patients.

Although long-term health issues from COVID-19 are a major public health concern, evidence on post-acute COVID-19 syndrome, or post-COVID-19, is still limited, specifically among children and adolescents.

Individuals with COVID-19 reinfections were twice as likely to die and three times more likely to be hospitalized than those who did not have COVID-19 multiple times.

In recent years, pharmacist roles have evolved as critically important caregivers who increasingly provide essential health care services far beyond medication dispensing.

New COVID-19 variants are always cause for concern but are not a cause for panic.

A session presenter at the ASCP 2022 Annual Meeting explained how the COVID-19 pandemic significantly magnified the importance of infection prevention and control practices in long-term care.

In addition to the ongoing COVID-19 pandemic, significant public health concerns include opioid overdoses, maternal mortality disparities, and climate change.

Pharmacy leaders and academics have been begging the profession to evolve for decades. It took a pandemic to make it happen.

Double-digit inflation, low reimbursement rates, and staffing shortages present obstacles.

Last year in particular, pharmacists played a greater role in patient care with an increased workload as they connected patients, providers, and payers.

Highest prevalence is seen among adults, outpatients, and women and can cause persistent severe anosmia or hyposmia, findings indicate.

Prior infection with SARS-CoV-2 decreased the risk of being reinfected with Omicron among unvaccinated and vaccinated individuals.

The risk of severe COVID-19 breakthrough infection was stronger with age and some comorbidities—the findings can inform antiviral distribution to prevent death or respiratory failure.

Many people wanted life to feel normal during the COVID-19 pandemic; however, this reason, among many, resulted in people not adhering to public health measures in the United States.

Because we need to be prepared and respond to future crises, making these changes permanent is a top priority for the profession of pharmacy.

Latest Information is key to helping patients stay healthy amid continuously changing landscape.

At month 6 post-COVID-19 infection, 123 patients received a diagnosis of type 1 diabetes (T1D) and only 72 were diagnosed with T1D at 6 months post-non-COVID-19 respiratory infection.

FDA revises emergency use authorization to grant prescribing authority for Pfizer’s Paxlovid antiviral treatment for COVID-19.

Take steps to safeguard prescribing, dispensing, and patient use of the COVID-19 antiviral medication.

Analyses of more than 30,000 adults in the United Kingdom from 9 prospective cohort studies finds a high pre-pandemic BMI was associated with the infection.

In a recent study, researchers observed that more than one-third of children with a primary immunodeficiency disease died from COVID-19.

Men with chronically low testosterone levels are more likely to be hospitalized from COVID-19 than those with normal levels, but testosterone therapy could decrease this risk.

Viral antigen levels in blood plasma can provide clinically important patient outcomes among hospitalized patients with COVID-19.

Children younger than age 6 years might be protected from other COVID-19 variants for up to a year after infection.

Analysis includes nearly 43 million individuals aged 13 year and older who received at least 1 dose in England between December 1, 2020, and December 15, 2021.

Overall low awareness of the Omicron variant infection contributed to high transmission rates and rapid spread of SARS-CoV-2 in communities.

University of Minnesota Medical School Analysis shows comparison with fluvoxamine and ivermectin in a double-blinded, placebo-controlled, randomized study.

Resources for health care professionals include FDA’s patient eligibility screening checklist tool for prescribers.

Investigators from University of Texas Health Science Center at Houston analyze data from individuals aged 5 to 18 years enrolled in the Texas CARES survey.

Researchers discovered that a common anti-inflammatory drug could lower the number of patients on ventilators from COVID-19, increasing the likelihood of survival by more than 50%.